Renal outcomes with sodium-glucose cotransporters 2 inhibitors in Patients with Type 2 Diabetes Mellitus with Chronic Kidney Disease Stages 3b-4.
Main Article Content
Abstract
Introduction: Randomized clinical trials have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors significantly reduce renal events in patients with type 2 diabetes mellitus (T2DM) at high risk for cardiovascular disease. However, these trials included only a small number of patients with moderate-to-severe chronic kidney disease (CKD), leaving the renoprotective effects of SGLT2 inhibitors in T2DM patients and impaired renal function unclear.
Methods: This retrospective study evaluated the effects of SGLT2 inhibitors on kidney function in T2DM patients with CKD stages 3b-4 with estimated glomerular filtration rate (eGFR) 15-45 mL/min/1.73 m². Conducted by a single nephrology group across two medical centers, the study included 175 T2DM patients who initiated SGLT2 inhibitor therapy and continued treatment for at least one year. The primary outcomes were changes in eGFR and urinary protein excretion over a one-year period.
Results: After one year of SGLT2 inhibitor therapy, the median eGFR showed no significant change from baseline. However, the annual decline in eGFR significantly improved, and urinary protein excretion decreased significantly. Despite these positive renal outcomes, HbA1c reduction was not significant.
Conclusion: This study demonstrated that SGLT2 inhibitors offer renoprotective benefits in T2DM patients with moderate-to-severe CKD by improving the annual decline in eGFR and reducing urinary protein excretion. Further prospective clinical studies are required to assess the long-term effects of SGLT2 inhibitors on glycemic control and renal function in this patient population.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Duru OK, Middleton T, Tewari MK, Norris K. The landscape of diabetic kidney disease in the United States. Curr Diab Rep. 2018;18(3):14.
3. Doshi SM, Friedman AN. Diagnosis and Management of Type 2 Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2017;12(8):1366–1373.
4. Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64(6):821–835.
5. Nojima J, Meguro S, Ohkawa N, Furukoshi M, Kawai T, Itoh H. One-year eGFR decline rate is a good predictor of prognosis of renal failure in patients with type 2 diabetes. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(9):746–754.
6. Tsimihodimos V, Filippatos TD, Filippas-Ntekouan S, Elisaf M. Renoprotective effects of SGLT2 inhibitors: beyond glucose reabsorption inhibition. Curr Vasc Pharmacol. 2017;15(2):96–102.
7. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075) :1238–1252.
8. Moen MF, Zhan M, Hsu VD, Walker LD, Einhorn LM, Seliger SL, Fink JC. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1121–1127.
9. Davies M, Chatterjee S, Khunti K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol. 2016; 8:61–81.
10. Neumiller JJ, Alicic RZ, Tuttle KR. Therapeutic considerations for antihyperglycemic agents in diabetic kidney disease. J Am Soc Nephrol. 2017; 28(8):2263–2274.
11. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–2045.
12. Sugiyama S, Jinnouchi H, Kurinami N, Hieshima K, Yoshida A, Jinnouchi K, Tanaka M, et al. Impact of dapagliflozin therapy on renal protection and kidney morphology in patients with uncontrolled type 2 diabetes mellitus. J Clin Med Res. 2018;10(6):466–477.
13. Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomized, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):610–621.
14. Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomized clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691–704.
15. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
16. Kelly MS, Lewis J, Huntsberry AM, Dea L, Portillo I. Efficacy, and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Postgrad Med. 2019; 131(1):31–42.
17. Dekkers CCJ, Wheeler DC, Sjostrom CD, Stefansson BV, Cain V, Heerspink HJL. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and stages 3b-4 chronic kidney disease. Nephrol Dial Transplant. 2018;33(11):2005–2011.
18. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701.
19. Heerspink HJ, Kropelin TF, Hoekman J, de Zeeuw D, Reducing Albuminuria as Surrogate Endpoint C. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol. 2015;26(8):2055–2064.
20. Cassis P, Locatelli M, Cerullo D, Corna D, Buelli S, Zanchi C, Villa S, et al. SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight. 2018;3(15)
21. Takagi S, Li J, Takagaki Y, Kitada M, Nitta K, Takasu T, Kanasaki K, et al. Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. J Diabetes Investig. 2018;9(5):1025–1032.
22. Tanaka S, Sugiura Y, Saito H, Sugahara M, Higashijima Y, Yamaguchi J, Inagi R, et al. Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice. Kidney Int. 2018;94(5):912–925.